Article Data

  • Views 339
  • Dowloads 125

Case Reports

Open Access Special Issue

Recurrence of low-grade serous ovarian cancer successfully treated with Gemcitabine and Bevacizumab: a case report and literature review

  • Hanako Sato1
  • Yasushi Kotani1,*,
  • Chiho Miyagawa1
  • Tamaki Yahata1
  • Kosuke Murakami1
  • Hidekatsu Nakai1
  • Tomoyuki Otani1
  • Noriomi Matsumura1

1Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, 589-8511 Osaka-sayama, Japan

DOI: 10.22514/ejgo.2022.049 Vol.43,Issue 5,October 2022 pp.107-111

Submitted: 31 May 2022 Accepted: 14 September 2022

Published: 15 October 2022

*Corresponding Author(s): Yasushi Kotani E-mail: y-kotani@med.kindai.ac.jp

Abstract

Ovarian low-grade serous carcinoma (LGSC) is usually a slow growing tumor with a relatively good prognosis. However, LGSC that have relapsed are highly resistant to chemotherapy, and there is currently no established treatment for them in contrast to high-grade serous carcinoma (HGSC). Here, we first review the literature on this topic and then describe a case of LGSC that relapsed and responded to Gemcitabine and Bevacizumab. The patient was a 37-year-old nulliparous woman who had undergone three cycles of topotecan after initial surgery at age 28.5 years as well as three months later during a disease-free interval. Intraperitoneal dissemination was observed and laparoscopic biopsy was performed. Histopathological examination revealed LGSC, and genetic testing revealed mutations in the neurofibromatosis type 1 (NF1) and TP53 genes. The mass of the disseminated lesion subsequently increased overall, and subileus was observed. The patient was treated, but the operation was incomplete. Postoperatively, Gemcitabine and Bevacizumab therapy was started. After six cycles, tumor markers became negative and Positron Emission Tomography-CT (PET-CT) showed decreased tumor activity. There were 20 cycles without any symptoms. LGSC is often resistant to anticancer drugs, but Gemcitabine and Bevacizumab therapy was able to suppress the lesions and symptoms in this case. With these findings, future genomic testing may assist in the treatment strategy for cases of LGSC recurrence, which are considered to be less likely to respond to anticancer drugs. Comprehensive genetic analysis will hopefully lead to the molecular mechanism of carcinogenesis for more effective and targeted therapies.


Keywords

Ovarian cancer; Low-grade serous carcinoma; Gemcitabine; Bevacizumab; Genetic mutation


Cite and Share

Hanako Sato,Yasushi Kotani,Chiho Miyagawa,Tamaki Yahata,Kosuke Murakami,Hidekatsu Nakai,Tomoyuki Otani,Noriomi Matsumura. Recurrence of low-grade serous ovarian cancer successfully treated with Gemcitabine and Bevacizumab: a case report and literature review. European Journal of Gynaecological Oncology. 2022. 43(5);107-111.

References

[1] Singer G, Stöhr R, Cope L, Dehari R, Hartmann A, Cao D, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low-and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. The American Journal of Surgical Pathology. 2005; 29: 218–224.

[2] Slomovitz B, Gourley C, Carey MS, Malpica A, Shih I, Huntsman D, et al. Low-grade serous ovarian cancer: state of the science. Gynecologic Oncology. 2020; 156: 715–725.

[3] Gershenson DM, Bodurka DC, Lu KH, Nathan LC, Milojevic L, Wong KK, et al. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. Journal of Clinical Oncology. 2015; 33: 2675–2682.

[4] Vang R, Shih I, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Advances in Anatomic Pathology. 2009; 16: 267–282.

[5] Shih I, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. The American Journal of Pathology. 2004; 164: 1511–1518.

[6] Kurman RJ, Carcangiu ML, Herrington S, Young RH. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. IARC: Lyon. 2014.

[7] Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, et al. Clinical behavior of stage II–IV low-grade serous carcinoma of the ovary. Obstetrics & Gynecology. 2006; 108: 361–368.

[8] Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecologic Oncology. 2009; 114: 48–52.

[9] Crane EK, Sun CC, Ramirez PT, Schmeler KM, Malpica A, Gershenson DM. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecologic Oncology. 2015; 136: 25–29.

[10] Dalton HJ, Fleming ND, Sun CC, Bhosale P, Schmeler KM, Gershenson DM. Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: a single institution experience. Gynecologic Oncology. 2017; 145: 37–40.

[11] Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, DeLair D, et al. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. International Journal of Gynecologic Cancer. 2014; 24: 1010–1014.

[12] Rose PG, Mahdi H, Jernigan A, Yang B. Activity of bevacizumab in patients with low-grade serous ovarian carcinoma. International Journal of Gynecologic Cancer. 2016; 26: 1048–1052.

[13] Rose PG, Roma A. Evidence of extended (>7 years) activity of bevacizumab and metronomic cyclophosphamide in a patient with platinum-resistant low-grade serous ovarian carcinoma. Anti-Cancer Drugs. 2013; 24: 986–988.

[14] Nickles Fader A, Java J, Ueda S, Bristow RE, Armstrong DK, Bookman MA, et al. Survival in women with grade 1 serous ovarian carcinoma. Obstetrics & Gynecology. 2013; 122: 225–232.

[15] Colombo N, Sessa C, Bois AD, Ledermann J, McCluggage W, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. International Journal of Gynecologic Cancer. 2019; 29: 728–760.

[16] Gershenson DM, Sun CC, Iyer RB, Malpica AL, Kavanagh JJ, Bodurka DC, et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecologic Oncology. 2012; 125: 661–666.

[17] Tang M, O’Connell RL, Amant F, Beale P, McNally O, Sjoquist KM, et al. PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. Gynecologic Oncology. 2019; 154: 531–538.

[18] Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. Journal of the National Cancer Institute. 2003; 95: 484–486.

[19] Van Nieuwenhuysen E, Busschaert P, Laenen A, Moerman P, Han SN, Neven P, et al. Loss of 1p36.33 frequent in low-grade serous ovarian cancer. Neoplasia. 2019; 21: 582–590.

[20] Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. The Lancet Oncology. 2013; 14: 134–140.

[21] Ishibashi T, Nakayama K, Razia S, Ishikawa M, Nakamura K, Yamashita H, et al. High frequency of PIK3CA mutations in low-grade serous ovarian carcinomas of Japanese patients. Diagnostics. 2019; 10: 13.

[22] Xu Y, Bi R, Xiao Y, Tu X, Li M, Li A, et al. Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary. Diagnostic Pathology. 2017; 12: 87.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top